ADC Therapeutics SA annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
ADC Therapeutics SA Stock-Based Compensation Growth & History (ADCT)
ADC Therapeutics SA's stock-based compensation was $6.9M for fiscal 2025.
View full ADC Therapeutics SA company overviewADC Therapeutics SA annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.9M | $337,000 | +5.13% |
| 2024 | 2024-12-31 | $6.6M | −$6.9M | −51.33% |
| 2023 | 2023-12-31 | $13.5M | −$37.1M | −73.35% |
| 2022 | 2022-12-31 | $50.6M | −$9.9M | −16.38% |
| 2021 | 2021-12-31 | $60.6M | $17.6M | +41.06% |
| 2020 | 2020-12-31 | $42.9M | $41.8M | +3743.15% |
| 2019 | 2019-12-31 | $1.1M | $648,000 | +138.17% |
| 2018 | 2018-12-31 | $469,000 | — | — |
ADC Therapeutics SA quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.5M | $2.7M | +151.24% |
| Q1 2026 | 2026-03-31 | $2.4M | $21,000 | +0.87% |
| Q4 2025 | 2025-12-31 | $673,000 | −$943,000 | −58.35% |
| Q3 2025 | 2025-09-30 | $2.0M | −$806,000 | −28.72% |
| Q2 2025 | 2025-06-30 | $1.8M | −$177,000 | −8.90% |
| Q1 2025 | 2025-03-31 | $2.4M | $2.3M | +1432.28% |
| Q4 2024 | 2024-12-31 | $1.6M | −$604,000 | −27.21% |
| Q3 2024 | 2024-09-30 | $2.8M | $723,000 | +34.71% |
| Q2 2024 | 2024-06-30 | $2.0M | $870,000 | +77.82% |
| Q1 2024 | 2024-03-31 | $158,000 | −$7.9M | −98.04% |
| Q4 2023 | 2023-12-31 | $2.2M | −$6.6M | −74.93% |
| Q3 2023 | 2023-09-30 | $2.1M | −$12.5M | −85.70% |
| Q2 2023 | 2023-06-30 | $1.1M | −$12.7M | −91.91% |
| Q1 2023 | 2023-03-31 | $8.1M | −$5.3M | −39.74% |
| Q4 2022 | 2022-12-31 | $8.9M | −$4.7M | −34.59% |
| Q3 2022 | 2022-09-30 | $14.6M | −$233,000 | −1.57% |
| Q2 2022 | 2022-06-30 | $13.8M | −$4.4M | −24.36% |
| Q1 2022 | 2022-03-31 | $13.4M | −$553,000 | −3.96% |
| Q4 2021 | 2021-12-31 | $13.5M | −$7.2M | −34.78% |
| Q3 2021 | 2021-09-30 | $14.8M | $3.8M | +34.67% |
| Q2 2021 | 2021-06-30 | $18.3M | $10.9M | +147.15% |
| Q1 2021 | 2021-03-31 | $14.0M | $10.2M | +268.10% |
| Q4 2020 | 2020-12-31 | $20.8M | — | — |
| Q3 2020 | 2020-09-30 | $11.0M | — | — |
| Q2 2020 | 2020-06-30 | $7.4M | — | — |
| Q1 2020 | 2020-03-31 | $3.8M | — | — |
ADC Therapeutics SA stock-based compensation trends
Over the last five fiscal years, ADC Therapeutics SA's stock-based compensation decreased from $42.9M to $6.9M, a change of −$36.0M. The latest reported quarter, Q2 2026, shows $4.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ADC Therapeutics SA source filings ↗